The Food and Drug Administration (FDA) approved the label expansion, citing the results of a multinational study that found that use of Wegovy caused symptoms. 20% decrease putting you at risk for serious adverse cardiovascular events.
The label change comes after more late-stage clinical trials. 17,000 people Those who received either Wegovy or a placebo.
Wegobee’s maker, Novo Nordisk, notes that benefits were observed among study participants regardless of “baseline age, sex, race, ethnicity, body mass index (BMI), or level of renal impairment.” did.
The active ingredients of Wegovy are: Semaglutide, part of a class of drugs known as GLP-1 agonists, so far only approved for use in the treatment of obesity and diabetes. Other commonly known drugs in this class include Ozempic, Mounjaro, and Zepbound.
Heart disease is main cause of death In the United States, according to the Centers for Disease Control and Prevention. Expanding the label could mean more insurance companies will cover the drug.
Medicare is forbidden Many private insurance companies balk at the cost, forcing patients who need the drug to pay thousands of dollars.Wegovy prices before discounts $1,300 Month.
Novo Nordisk says the label expansion now makes Wigovy a drug that can help people manage their weight and also help prevent the risk of life-threatening heart disease.
Like other GLP-1 therapeutics, Wegovy remains shortage That’s because manufacturers are struggling to keep up with demand. Last month, Novo Nordisk Improved availability Overall supply is expected to increase gradually throughout this year.
